Blood Stream Infections Clinical Trial
Official title:
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Verified date | July 2014 |
Source | University of Houston |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Susceptibility testing is commonly employed in patients with bacterial infections in order to guide rational use of antibiotics; however, the use of antifungal susceptibility testing is limited due to lack of availability, costs, and delays in receiving results. The goals of antifungal susceptibility testing should mirror those of antibacterial susceptibility testing: to predict clinical response or failure. Additionally, susceptibility reports should be used as a guide for physicians when transitioning patients from parenteral to oral antifungal agents. Currently, it is unknown whether antifungal susceptibility testing impacts treatment decisions in hospitals that routinely perform Candida susceptibility testing. The purpose of this study is to evaluate the changes in antifungal treatment based on in vitro susceptibility reports and how these decisions affect mortality, recurrence of infection, and length of hospital stay in candidemia patients.
Status | Completed |
Enrollment | 450 |
Est. completion date | January 2011 |
Est. primary completion date | January 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Hospitalized patients with bloodstream infections due to Candida species Exclusion Criteria: - Patients will be excluded from this study if their medical charts contain incomplete outcome or susceptibility data. Patients treated empirically or definitively with amphotericin-based products will also be excluded |
Observational Model: Cohort, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Houston | Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess empiric choice of antifungal therapy in hospitalized patients with candidemia. | Assessments made for 30-days after postivie blood culture | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04874441 -
Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
|
N/A | |
Recruiting |
NCT00697944 -
Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
|
Phase 4 | |
Completed |
NCT00109525 -
Early Diagnosis of Candidiasis in Premature Infants
|
||
Completed |
NCT05614726 -
A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study
|
N/A | |
Completed |
NCT00818584 -
An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
|
Phase 1 | |
Completed |
NCT00366223 -
Changing Patterns of Candida Infections in Urban Medical Centers
|
||
Completed |
NCT03212729 -
Antimicrobial Photodynamic Therapy Associated With the Conventional Endodontic Treatment: A Clinical and Microbiological Study
|
N/A | |
Completed |
NCT00058682 -
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
|
Phase 3 |